Lipoatrophy following weekly growth hormone therapy: A case report

Hazer I., Bas V. N.

Journal of Pediatric Endocrinology and Metabolism, vol.38, no.10, pp.1098-1102, 2025 (SCI-Expanded, Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 10
  • Publication Date: 2025
  • Doi Number: 10.1515/jpem-2025-0214
  • Journal Name: Journal of Pediatric Endocrinology and Metabolism
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, MEDLINE
  • Page Numbers: pp.1098-1102
  • Keywords: lipoatrophy, long-acting growth hormone, side effect, somatrogon
  • Kütahya Health Sciences University Affiliated: Yes

Abstract

Traditional daily recombinant human growth hormone injections can be burdensome for patients and caregivers, leading to compliance issues. Long-acting growth hormone formulations have been developed to overcome these challenges. We report a 7-year-old girl who developed severe lipoatrophy secondary to repeated somatrogon injections at the same anatomical site during the third month of therapy, with complete resolution after 10 weeks of treatment discontinuation. To our knowledge, this is only the second reported case of somatrogon-induced lipoatrophy in the literature. This case also showed that lipoatrophy developing as a result of somatogron treatment is a reversible side effect.